NCT04067986

Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer

Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer：One-arm Exploratory Clinical Trial

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 62 (estimated)
• Sponsor: Zhongshan Hospital Xiamen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The efficacy and safety of the use of Camrelizumab combined with Apatinib

Detailed description

To evaluate the clinical efficacy and safety of Camrelizumab combined with Apatinib in the treatment of patients with advanced gastric cancer and colorectal cancer. The 62 patients were enrolled in a 2-week regimen with 200mg Camrelizumab given intravenously every two weeks and 250mg apatinib mesylate every 4 weeks for a treatment cycle until progressive or intolerable，then the objective remission rate(ORR) was calculated.

Conditions

• Colorectal Cancer Recurrent

Interventions

Type	Name	Description
DRUG	Camrelizumab	Camrelizumab One course will last 28 days.Intravenous injection at a dose of 200 mg, q2w One course will last 28 days. Oral administration at a dose of 250 mg/d
DRUG	Apatinib	Apatinib One course will last 28 days.Oral administration at a dose of 250 mg, qd

Timeline

• Start date: 2019-08-20
• Primary completion: 2020-09-23
• Completion: 2021-10-31
• First posted: 2019-08-28
• Last updated: 2020-09-29

Locations

1 site across 1 country: China